T-Cell-Engaging Bispecific Antibodies in Cancer: What the Non-Oncology Pharmacist Needs to Know about Acute Toxicities
ACPE Activity Number:0204-0000-26-079-H01-P Release Date:05/23/2026 Expiration Date:05/23/2029 Activity Type: Knowledge-based CE Credits: 0.5 contact hour, no partial credit Activity Fee: Member – Free / Non-Member – Not Available
Activity Overview
T-cell-engaging bispecific antibodies have proven to be challenging therapies to implement and delivery in the oncology realm across the US. Pharmacists not practicing in oncology are likely unfamiliar with these drugs and may have difficulty identifying them as well as being unfamiliar with their unique toxicities and the different guidelines for adverse event management.Pharmacists lack strategies for the prevention and management of bispecific antibody associated T-cell-mediated toxicities and there are multiple guidelines published for management of bispecific antibody associated toxicities, and there is a lack of consistency between them. This podcast will review these.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
Pharmacists who may encounter patients on T-Cell-Engaging Bispecific Antibodies who present to the Emergency Department with signs and symptoms of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).
After completing this activity, the learner should be able to:
Describe the mechanism of action and safety profile of T-cell-engaging bispecific antibodies used in the treatment of cancer
Discuss strategies for the prevention, monitoring, and management of acute toxicities associated with T-cell-redirection, including cytokine release syndrome and neurologic toxicity
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.
Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Once you have processed and claimed your CE credit, we encourage you to check your NABP eProfile account to verify your credits were transferred successfully before the ACPE 60-day deadline. It is an electronic direct-report process so your credits should appear in your account within a few minutes. After the 60 day deadline, ASHP will no longer be able to report your credit(s) for this activity.
